Jasmina Uvalic

发表

Mutation Yield of a Custom 212-Gene Next-Generation Sequencing Panel for Solid Tumors: Clinical Experience of the First 260 Cases Tested Using the JAX ActionSeq™ Assay

G. Ananda, H. Reddi, Q. Nie, 2019, Molecular Diagnosis & Therapy.

Technical and Regulatory Considerations for Taking Liquid Biopsy to the Clinic: Validation of the JAX PlasmaMonitorTM Assay

G. Ananda, H. Reddi, L. Holinka, 2019, Biomarker insights.

Genomic Profiling of Two Histologically Distinct Rare Urothelial Cancers in a Clinical Setting to Identify Potential Therapeutic Options for Treatment and Management of Disease

H. Reddi, J. Rueter, Pavalan Selvam, 2018, Case Reports in Oncology.

Molecular profiling of CNS tumors for the treatment and management of disease

H. Reddi, Q. Nie, J. Rueter, 2019, Journal of Clinical Neuroscience.

Molecular profiling of gynecologic cancers for treatment and management of disease - demonstrating clinical significance using the AMP/ASCO/CAP guidelines for interpretation and reporting of somatic variants.

H. Reddi, Q. Nie, J. Rueter, 2020, Cancer genetics.

2-1-2019 Technical and Regulatory Considerations for Taking Liquid Biopsy to the Clinic : Validation of the JAX PlasmaMonitor

G. Ananda, H. Reddi, L. Holinka, 2019 .

Mutation Yield of a Custom 212-Gene Next-Generation Sequencing Panel for Solid Tumors: Clinical Experience of the First 260 Cases Tested Using the JAX ActionSeq™ Assay

G. Ananda, H. Reddi, Q. Nie, 2019, Molecular Diagnosis & Therapy.

The Jackson Laboratory for Genomic Medicine ActionSeq Plus Offering Provides a Comprehensive Analysis of Cancer Diagnoses: 332

G. Ananda, H. Reddi, Jasmina Uvalic, 2018 .